Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Controversial Chinese gene-therapy drug entering unfamiliar territory

Experience in clinic is raising issues that Western researchers will not have seen before

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Within years, China has caught up to Europe in the number of gene-therapy treatments in development.
Figure 2: Global trends: China is at the forefront of countries with late stage gene therapy treatments for cancer (Phase II or later).
Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jia, H. Controversial Chinese gene-therapy drug entering unfamiliar territory. Nat Rev Drug Discov 5, 269–270 (2006). https://doi.org/10.1038/nrd2017

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2017

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing